Article
Endocrinology & Metabolism
Lionel Groussin, Helene Theodon, Laura Bessiene, Leopoldine Bricaire, Fideline Bonnet-Serrano, Beatrix Cochand-Priollet, Karen Leroy, Simon Garinet, Eric Pasmant, Jeremie Zerbit, Romain Seban, Francois Goldwasser, Jerome Clerc, Anne Segolene Cottereau, Olivier Huillard
Summary: Inhibitors may treat RAI-resistant cancers by activating RAI and providing antitumoral effects, but not all patients experience redifferentiation.
Article
Pharmacology & Pharmacy
Bo Shi, Wenbiao Ma, Hongshuai Pan, Yang Shi, Huan Zhang, Shenghai Xing
Summary: This study evaluated the cost-effectiveness of apatinib and cabozantinib for RAIR-DTC from the perspective of the Chinese healthcare system. The results showed that apatinib is cost-effective compared to placebo, while cabozantinib may not be cost-effective and a reduction in price is warranted.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Ping Dai, Wanjun Zhao, Xun Zheng, Han Luo, Xiaofei Wang
Summary: By analyzing data from a database, this study found that radioactive iodine therapy may not improve cancer-specific survival in patients with tall cell variant papillary thyroid cancer after total thyroidectomy.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Shijie Yang, Jing Zhan, Xiequn Xu
Summary: This study aimed to investigate whether progression-free survival (PFS) could be used as a surrogate endpoint for overall survival (OS) in locally advanced or metastatic differentiated thyroid cancer (DTC) clinical trials. The results showed weak correlation between PFS benefit and OS benefit, and PFS did not meet the statistical criteria for the surrogate endpoint.
Article
Endocrinology & Metabolism
Yuanna Ling, Xiaoli Xiong, Jiaxin Luo, Quanliang Zou, Pan Chen, Liqin Pan, Man Long, Huijuan Feng, Wei Ouyang
Summary: This study aims to demonstrate the clinical efficacy and safety of sorafenib used in the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC) at Zhujiang Hospital of Southern Medical University. The results showed that sorafenib has promising efficacy in RR-DTC, especially in patients with lung metastasis and lung-only metastasis. The main adverse effect of sorafenib was hand-foot skin syndrome (HFS).
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Tian Tian, Shuhui Huang, Hongyuan Dai, Mengfang Qi, Bin Liu, Rui Huang
Summary: This study investigated the clinicopathologic characteristics and prognosis of radioactive iodine-refractory (RAIR) papillary thyroid cancer in children, adolescents, and young adults. It found that younger patients are more susceptible to developing RAIR disease, which leads to unfavorable progression-free survival and disease-specific survival. RAIR disease was also identified as an independent predictor of progressive disease.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Pharmacology & Pharmacy
Sophie Leboulleux, Livia Lamartina, Julien Hadoux, Eric Baudin, Martin Schlumberger
Summary: This paper discusses the refractoriness to RAI treatment and the optimization of treatment initiation and choice. Clinical trials show that anti-angiogenic kinase inhibitors and targeted inhibitors have high response rates in improving survival. Treatment sequencing and targeted therapies still pose challenges and further research is needed.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2022)
Article
Endocrinology & Metabolism
Marcia S. S. Brose, Johannes W. A. Smit, Chia-Chi Lin, Masayuki Tori, Daniel W. W. Bowles, Francis Worden, Daniel Hueng-Yuan Shen, Shih-Ming Huang, Hui-Jen Tsai, Maria Alevizaki, Robin P. P. Peeters, Shunji Takahashi, Pavel Rumyantsev, Rongjin Guan, Svetlana Babajanyan, Kirhan Ozgurdal, Iwao Sugitani, Fabian Pitoia, Livia Lamartina
Summary: Sorafenib and lenvatinib are approved for RAI-R DTC, but there is no consensus on when to initiate MKI treatment. This study evaluated TTSP in patients with RAI-R DTC for whom the decision to treat with an MKI was made at study entry. The results showed that most patients had a TTSP of 36 months or more, indicating a positive impact of MKIs on patient prognosis.
Article
Endocrinology & Metabolism
Youwen Zhu, Kun Liu, Kailing Wang, Libo Peng
Summary: The study revealed that apatinib was more cost-effective compared to lenvatinib in the first-line treatment of Chinese patients with RAIR-DTC, as indicated by network meta-analysis and cost-effectiveness analysis results.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Matthew D. Ringel
Summary: Treatment of progressive metastatic follicular cell-derived and medullary thyroid cancers is challenging, with limited complete remissions, short response durations, and common toxicities. Further research into resistance mechanisms, biomarker development, and new therapeutic strategies is needed.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Pharmacology & Pharmacy
Hongxiu Luo, Andrew Tobey, Sungyoung Auh, Craig Cochran, Noha Behairy, Maria Merino, Marina Zemskova, Joanna Klubo-Gwiezdzinska
Summary: This study investigated the association between UIE and PFS in patients with DTC undergoing RAI therapy. It found that patients with UIE >= 200μg/day may have a higher risk of disease progression during treatment, while distant metastases were identified as a strong independent predictor of progression. Adjusting iodine intake could help reduce the risk of progression for patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Xiaofei Wang, Xun Zheng, Jingqiang Zhu, Zhihui Li, Tao Wei
Summary: In this study, the effect of radioactive iodine (RAI) therapy on cancer-specific survival (CSS) in Hurthle cell carcinoma (HCC) patients was investigated. The results showed that RAI treatment did not significantly improve CSS in HCC patients, regardless of the presence of aggressive features.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Yan-Song Lin, Hui Yang, Yong Ding, Yi-Zhuang Cheng, Feng Shi, Jian Tan, Zhi-Yong Deng, Zhen-Dong Chen, Rong-Fu Wang, Qing-Hai Ji, Rui Huang, Lin-Fa Li
Summary: The study evaluated the efficacy and safety of the new multikinase inhibitor donafenib in treating locally advanced or metastatic RAIR-DTC. Both 200mg and 300mg doses of donafenib showed similar efficacy in terms of objective response rate, with the 300mg dose demonstrating a trend towards longer progression-free survival and more tumor shrinkage. The most common grade 3 treatment-related adverse events were palmar-plantar erythrodysesthesia and hypertension.
Review
Medicine, General & Internal
Debbie W. Chen, Brian H. H. Lang, Donald S. A. McLeod, Kate Newbold, Megan R. Haymart
Summary: The past 5-10 years have seen significant advancements in the diagnosis and management of thyroid cancer, including ultrasound-based risk stratification systems, less invasive alternatives to surgery, and the availability of new systemic therapies for advanced cases. However, disparities in thyroid cancer care still exist, highlighting the importance of population-based studies and inclusive research to address barriers to equitable care.
Review
Oncology
Fadi Nabhan, Priya H. Dedhia, Matthew D. Ringel
Summary: The diagnosis and management of patients with follicular cell-derived thyroid cancer has evolved to be more personalized over recent decades, with advancements in molecular technologies enabling tailored treatment options for patients with more aggressive forms of the disease. Guidelines from various societies worldwide emphasize the importance of an individualized approach to clinical management in this field.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Biotechnology & Applied Microbiology
I Vieco-Marti, A. Lopez-Carrasco, L. de la Cruz-Merino, R. Noguera, T. Alvaro Naranjo
Summary: Skin tumours are highly responsive to immunotherapy, but drug resistance is still a challenge. It is crucial to study the mechanisms of response and resistance to immunotherapy. Currently, there are predictive biomarkers for treatment response and warning biomarkers for possible resistance, as well as emerging markers. Comprehensive understanding of the biology, health, and disease of skin tumours is fundamental for accurate diagnosis and selection of therapeutic protocols.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
(2022)
Article
Medicine, General & Internal
Jason J. Luke, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz-Merino, Muhammad A. Khattak, Dirk Schadendorf, Georgina Long, Paolo A. Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Jean-Jacques Grob, Caroline Robert, Matteo S. Carlino, Peter Mohr, Andrew Poklepovic, Vernon K. Sondak, Richard A. Scolyer, John M. Kirkwood, Ke Chen, Scott J. Diede, Sama Ahsan, Nageatte Ibrahim, Alexander M. M. Eggermont
Summary: The study demonstrates that Pembrolizumab as adjuvant therapy significantly prolongs recurrence-free survival in patients with stage II melanoma, with manageable safety profile.
Article
Immunology
Carlos Martinez-Chinchilla, Lucia Vazquez-Montero, Natalia Palazon-Carrion, Isabel M. Fernandez-Roman, Jose Lopez-Barba, Luis De la Cruz-Merino, Jesus Rodriguez-Bano, Zaira R. Palacios-Baena
Summary: Immunosuppressant patients, such as those with hematological malignancies, have a higher risk of SARS-CoV-2 infection. This study presents two cases of B-cell lymphoma patients treated with rituximab who experienced recurrent flares of COVID-19 after acute infection. These cases highlight the unresolved issue of COVID-19 in immunosuppressant patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Daniel J. Garcia-Dominguez, Lourdes Hontecillas-Prieto, Natalia Palazon-Carrion, Carlos Jimenez-Cortegana, Victor Sanchez-Margalet, Luis de la Cruz-Merino
Summary: Research on the tumor microenvironment and its role in the progression and immunosuppression of lymphoma and other cancers has led to a better understanding of the disease. Epigenetic mechanisms play a crucial role in the interaction between tumor cells and the surrounding components, promoting tumor survival and progression. This review summarizes the complex interaction between lymphoma tumor cells and immune cells, as well as the epigenetic alterations resulting from this cross-talk, highlighting the value of epigenetic modifications as biomarkers and therapeutic options.
Article
Oncology
Chau Dang, Michael S. Ewer, Suzette Delaloge, Jean-Marc Ferrero, Ramon Colomer, Luis de la Cruz-Merino, Theresa L. Werner, Katherine Dadswell, Mark Verrill, Daniel Eiger, Sriparna Sarkar, Sanne Lysbet de Haas, Eleonora Restuccia, Sandra M. Swain
Summary: The BERENICE study assessed the cardiac safety of neoadjuvant-adjuvant therapy for high-risk, HER2-positive early breast cancer. The study confirmed that pertuzumab-trastuzumab-based therapies are the standard of care for this patient population, with no new cardiac issues reported.
Article
Oncology
Natalia Palazon-Carrion, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Carlos Jimenez-Cortegana, Fernando Carnicero-Gonzalez, Eduardo Rios-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodriguez-Garcia, Ruben Fernandez-Alvarez, Natividad Martinez-Banaclocha, Josep Guma-Padro, Jose Gomez-Codina, Antonio Salar-Silvestre, Delvys Rodriguez-Abreu, Laura Galvez-Carvajal, Jorge Labrador, Maria Guirado-Risueno, Daniel J. Garcia-Dominguez, Lourdes Hontecillas-Prieto, Pablo Espejo-Garcia, Isabel Fernandez-Roman, Mariano Provencio-Pulla, Margarita Sanchez-Beato, Marta Navarro, Lejeune Marylene, Tomas Alvaro-Naranjo, Maria Casanova-Espinosa, Victor Sanchez-Margalet, Antonio Rueda-Dominguez, Luis de la Cruz-Merino
Summary: The R2-GDP schedule demonstrates feasibility and high activity in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). The regimen is able to reverse refractoriness to rituximab and shows significant efficacy in the primary refractory population. Additionally, monitoring immune biomarkers showed differences between responders and progressors.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
James Larkin, Jeffrey Weber, Michele Del Vecchio, Helen Gogas, Ana M. Arance, Stephane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O. Butler, Anna Marie Di Giacomo, Mark R. Middleton, Luis De la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil Khushalani, Paola Queirolo, Georgina Long, Maurice Lobo, Margarita Askelson, Paolo A. Ascierto, Mario Mandala
Summary: This study compared the long-term effectiveness of nivolumab as adjuvant therapy for melanoma based on AJCC-8 staging criteria with the results from AJCC-7. The results showed that nivolumab maintained its superior efficacy over ipilimumab in patients with resected stage III melanoma according to AJCC-8 analysis. The outcomes of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were consistent between AJCC-7 and AJCC-8 staging criteria.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
L. de la Cruz-Merino, M. Gion, J. Cruz, J. L. Alonso-Romero, V Quiroga, F. Moreno, R. Andres, M. Santisteban, M. Ramos, E. Holgado, J. Cortes, E. Lopez-Miranda, A. Cortes, F. Henao, N. Palazon-Carrion, L. M. Rodriguez, I Ceballos, A. Soto, A. Puertes, M. Casas, S. Benito, M. Chiesa, S. Bezares, R. Caballero, C. Jimenez-Cortegana, V Sanchez-Margalet, F. Rojo
Summary: This study evaluated a new chemoimmunotherapy combination of pembrolizumab and gemcitabine in HER2- advanced breast cancer patients. Although the objective response rate was not met, 22% of patients remained on treatment for over 6 months.
Review
Biochemistry & Molecular Biology
Carlos Jimenez-Cortegana, Lourdes Hontecillas-Prieto, Daniel J. Garcia-Dominguez, Fernando Zapata, Natalia Palazon-Carrion, Maria L. Sanchez-Leon, Malika Tami, Antonio Perez-Perez, Flora Sanchez-Jimenez, Teresa Vilarino-Garcia, Luis De la Cruz-Merino, Victor Sanchez-Margalet
Summary: Obesity is considered a pandemic and a risk factor for various types of cancers, including lymphoma, due to its promotion of an inflammatory state. Leptin, as a key adipokine, has been studied for its potential role in connecting obesity and lymphomas.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Marylene Lejeune, Laia Reverte, Noelia Gallardo, Esther Sauras, Ramon Bosch, Daniel Mata, Albert Roso, Anna Petit, Vicente Peg, Francisco Riu, Joan Garcia-Fontgivell, Fernanda Relea, Begona Vieites, Luis de la Cruz-merino, Meritxell Arenas, Valeri Rodriguez, Juana Galera, Anna Korzynska, Benoit Plancoulaine, Tomas Alvaro, Carlos Lopez
Summary: This study characterized the residual tumor microenvironment in 96 TNBC patients and evaluated its prognostic implications for partial responders vs. non-responders. Partial responders showed higher levels of CD83+ mature dendritic cells, FOXP3+ regulatory T cells, and IL-15 expression but lower CD138+ cell concentration, leading to improved overall survival and recurrence-free survival. However, MMP-9 expression in the residual tumor microenvironment was identified as an independent factor associated with the impaired response to neoadjuvant chemotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Pablo Rodriguez de Vera Gomez, Mariola Mendez Muros, Alberto Torres Cuadro, Francisco Javier Toyos Saenz de Miera, Rocio Lopez Ruiz, Raquel Guerrero Vazquez, Juan Jesus Garcia Gonzalez, Antonio Manuel Garrido Hermosilla, Tomas Martin Hernandez
Summary: This study describes the clinical and biochemical characteristics of GD-ALZ and the clinical course of GO-ALZ cases in patients treated with Alemtuzumab for RRMS. GD-ALZ was observed in 32.6% of the cases, mainly affecting women with an average age of 41.9 years. Having first-degree relatives with hypothyroidism was identified as a risk factor. GO-ALZ was diagnosed in 13.6% of the cases, with 3 cases requiring anti-IL-6 treatment.
JOURNAL OF NEUROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Maria Luisa Sanchez-Leon, Carlos Jimenez-Cortegana, Silvia Silva Romeiro, Carmen Garnacho, Luis de la Cruz-Merino, Daniel J. Garcia-Dominguez, Lourdes Hontecillas-Prieto, Victor Sanchez-Margalet
Summary: Breast cancer is the most diagnosed tumor in women with diverse molecular profiles. Despite the advancements in early detection and therapy, patients with metastatic disease have low survival rates. Immunotherapy, due to its ability to modulate the immune system, has emerged as a promising alternative. This review focuses on the new immunotherapies in breast cancer in the last five years and discusses the role of myeloid-derived suppressor cells as a therapeutic target.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Ana Pinar-Gutierrez, Ana R. Romero-Lluch, Suset Duenas-Disotuar, Irene de Lara-Rodriguez, Maria Angeles Galvez-Moreno, Tomas Martin-Hernandez, Jorge Garcia-Aleman, Guillermo Martinez-de Pinillos, Elena Navarro-Gonzalez
Summary: This study describes the characteristics, survival, and prognostic factors of a cohort of patients with bone metastases from differentiated thyroid carcinoma. The overall survival at 5 and 10 years was lower in patients who were not treated with I131, had nodal involvement, and/or had other metastases.
EUROPEAN THYROID JOURNAL
(2023)
Review
Otorhinolaryngology
Teresa Cambil-Molina, Tomas Martin-Hernandez
Summary: This article describes the use of various signaling techniques to improve surgical and therapeutic outcomes for patients with papillary thyroid carcinoma, with a special focus on the application of radioactive seed localization.